Polyclonal Antibody to Receptor Interacting Serine Threonine Kinase 1 (RIPK1)
| Code | Size | Price |
|---|
| PAE640Ra01-20ul | 20ul | £92.00 |
Quantity:
| PAE640Ra01-100ul | 100ul | £173.00 |
Quantity:
| PAE640Ra01-200ul | 200ul | £234.00 |
Quantity:
| PAE640Ra01-1ml | 1ml | £539.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Rat
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
RIP; Receptor-Interacting Protein; Cell death protein RIP; Serine/threonine-protein kinase RIP
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Receptor Interacting Serine Threonine Kinase 1
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;1:480-1900<br/>Immunohistochemistry: 5-20ug/mL;1:48-190<br/>Immunocytochemistry: 5-20ug/mL;1:48-190<br/>Optimal working dilutions must be determined by end user.
References
https://www.ncbi.nlm.nih.gov/pubmed/31788760;
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Receptor Interacting Serine Threonine Kinase 1 (RIPK1) | RPE640Ra01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||